Beijing Chunlizhengda Medical Instruments Co (688236) Fair Value & Analysis
Healthcare · CN · Market cap 5.8B CNY
Fair value as of: Jul 7, 2026
From 26 valuation models · updated 34 days ago
Fair value updated Jul 7, 2026, revised from ¥20.86 to ¥15.37 (−26.3%) since Jun 24, 2026. Share price −0.2% over the past month.
A strong business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥11.72 (bear) to ¥18.47 (bull), base ¥15.37. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 79/100 (high quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
55‑month range ¥10.31 – ¥35.15 · fair‑value band ¥11.72 – ¥18.47 · the ¥15.12 price screens below the ¥15.37 fair value. Dashed = 300-day average. As of Jul 7, 2026.
Analysis
Beijing Chunlizhengda Medical Instruments Co (688236) currently trades at ¥15.12, while our model-based Fair Value estimate is ¥15.37, implying the stock looks roughly 1.7% fairly valued today. The Quality Score stands at 79/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Beijing Chunlizhengda Medical Instruments Co generated revenue of 1.0B CNY at a net margin of 26.7%. Revenue declined 5.6% year over year. It earns a return on equity of 9.3%. The balance sheet holds a net cash position of 1.1B CNY. Fundamentals as of Jul 7, 2026
Our scenario range runs from ¥11.72 (bear case) to ¥18.47 (bull case); at ¥15.12, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 2%, 688236 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥22.11) versus Dividend Discount (¥0.7400). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beijing Chunlizhengda Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China and internationally.
Full company description
Beijing Chunlizhengda Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China and internationally. The company offers orthopedic medical devices and tissue repair products, including spine, trauma, joint, sports medicine, and bone repair material implants; surgical instrumentation products; platelet-rich plasma preparation kits; and closed wound negative pressure drainage kits. It also provides surgical robots; joint, spinal, sports medicine, trauma, oral care, and endoscopic products; orthopedic power products; and platelet-rich plasma preparation system products, as well as alloy materials and surgical powering equipment. The company exports its products to approximately 68 countries. The company was formerly known as Chunli Limited and changed its name to Beijing Chunlizhengda Medical Instruments Co., Ltd. in September 2010. Beijing Chunlizhengda Medical Instruments Co., Ltd. was incorporated in 1998 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beijing Chunlizhengda Medical Instruments Co reported revenue of ¥1.0B in FY2025 versus ¥1.1B in FY2021, a compound −1.5%/yr. Reported net income was ¥272M in FY2025, compounding −4.1%/yr from FY2021.
Watch 688236: get an alert when its fair value changes →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Beijing Chunlizhengda Medical Instruments Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beijing Chunlizhengda Medical Instruments Co (688236) overvalued or undervalued?
What is the fair value of 688236?
What is the quality score of 688236?
What is the revenue of Beijing Chunlizhengda Medical Instruments Co (688236)?
What is the net profit margin of 688236?
Does Beijing Chunlizhengda Medical Instruments Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beijing Chunlizhengda Medical Instruments Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.